<Li> For continuous outcome data, analysis of covariance (e.g., for changes in blood lipid levels after receipt of atorvastatin after acute coronary syndrome) tests the effects of predictor variables . </Li> <Li> For time - to - event outcome data that may be censored, survival analysis (e.g., Kaplan--Meier estimators and Cox proportional hazards models for time to coronary heart disease after receipt of hormone replacement therapy in menopause) is appropriate . </Li> <P> Regardless of the statistical methods used, important considerations in the analysis of RCT data include: </P> <Ul> <Li> Whether an RCT should be stopped early due to interim results . For example, RCTs may be stopped early if an intervention produces "larger than expected benefit or harm", or if "investigators find evidence of no important difference between experimental and control interventions ." </Li> <Li> The extent to which the groups can be analyzed exactly as they existed upon randomization (i.e., whether a so - called "intention - to - treat analysis" is used). A "pure" intention - to - treat analysis is "possible only when complete outcome data are available" for all randomized subjects; when some outcome data are missing, options include analyzing only cases with known outcomes and using imputed data . Nevertheless, the more that analyses can include all participants in the groups to which they were randomized, the less bias that an RCT will be subject to . </Li> <Li> Whether subgroup analysis should be performed . These are "often discouraged" because multiple comparisons may produce false positive findings that cannot be confirmed by other studies . </Li> </Ul>

Which of the following is not a characteristic of randomized control trials